CEL-SCI has announced that it is expanding the pre-clinical testing of its flu vaccine, utilizing its proprietary LEAPS technology (Ligand Epitope Antigen Presentation System). The testing is intended to determine its efficacy against more virulent strain of H1N1 swine and other influenza viruses.
The company has begun pre-clinical formulation, evaluation and testing of a new application of its LEAPS vaccine, which will allow the targeting of mutated versions of H1N1 swine and other influenza viruses.
Daniel Zimmerman, Inventor of the LEAPS technology and a consultant to CEL-SCI, said: Data showed that LEAPS vaccines were able to induce these protective immune responses without the excessive induction of pro-inflammatory cytokines. This is thought to be very important in the swine flu, or the avian flu, since it appears that the excessive production of pro-inflammatory cytokines during the course of the disease is responsible for and may lead to the increased number of deaths from these illnesses.